72392
document
The VA augmentation and switching treatments for improving depression outcomes ( VAST-D ) study : Rationale and design considerations . Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant , we designed a trial of three " next-step " strategies : switching to another antidepressant ( bupropion-SR ) or augmenting the current antidepressant with either another antidepressant ( bupropion-SR ) or with an atypical antipsychotic ( aripiprazole ) . The study will compare 12-week remission rates and , among those who have at least a partial response , relapse rates for up to 6 months of additional treatment . We review seven key efficacy/effectiveness design decisions in this mixed " efficacy-effectiveness " trial .
72393
Intervention_Physical
VA augmentation
72394
Intervention_Pharmacological
and
72395
Intervention_Physical
switching treatments
72396
Intervention_Physical
switching to another antidepressant (
72397
Intervention_Pharmacological
bupropion-SR
72398
Intervention_Physical
)
72399
Intervention_Pharmacological
augmenting the current antidepressant with either another antidepressant ( bupropion-SR ) or with an atypical antipsychotic ( aripiprazole )
72400
Outcome_Physical
12-week remission rates
72401
Outcome_Physical
relapse rates
72402
Participant_Condition
Major Depressive Disorder